Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Connective Tissue Cell Types01:22

Connective Tissue Cell Types

3.4K
Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

872
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
872
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

745
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
745
Introduction to Connective Tissues01:11

Introduction to Connective Tissues

19.0K
Connective tissues are one of the four main tissue types in humans that are extensively present in the body. They are characterized by cells embedded in an extracellular matrix (ECM) composed of a ground substance and three main types of protein fibers— collagen, elastic, and reticular fibers. The ground substance of connective tissues can range from a watery and jelly-like consistency to mineralized and hard. The wide variety of cells in the connective tissues include fibroblasts,...
19.0K
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

29
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
29

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Tirbanibulin 1% real-world use in 679 actinic keratoses patients during warm season (SUMM-AK study).

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

The impact of antibiotic therapy in psoriasis patients with active streptococcal infection: A prospective study.

The Journal of dermatology·2025
Same author

Reply to 'New onset of systemic lupus erythematosus following COVID-19 mRNA vaccination'.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Lepromatous leprosy presenting with erythema nodosum leprosum mimicking Bechet's disease.

Travel medicine and infectious disease·2022
Same author

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Related Experiment Video

Updated: Apr 27, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K

Drug induction in connective tissue diseases.

A Verdelli1, E Antiga, V Bonciolini

  • 1Department of Surgery and Translational Medicine, Section of Dermatology, Section of Dermatology University of Florence, Florence, Italy - alice.verdelli@hotmail.it.

Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|July 1, 2014
PubMed
Summary

Certain medications can trigger or worsen connective tissue diseases (CTDs). This review examines the causal link between drug exposure and specific CTDs like dermatomyositis and systemic sclerosis.

More Related Videos

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
11:03

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model

Published on: October 30, 2019

8.2K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

Related Experiment Videos

Last Updated: Apr 27, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K
A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
11:03

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model

Published on: October 30, 2019

8.2K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Connective tissue diseases (CTDs) are acquired autoimmune disorders.
  • Drug-induced (DI) syndromes are recognized, with drug-induced lupus being well-documented.
  • Emerging evidence links other CTDs to specific substance exposures.

Purpose of the Study:

  • To review and evaluate the causality between drug exposure and connective tissue diseases.
  • To focus on drug-induced dermatomyositis (DM) and morphea/systemic sclerosis (SSc).

Main Methods:

  • Systematic review of published case reports.
  • Analysis of temporal association between drug exposure and CTD onset.
  • Evaluation of causality using established criteria.

Main Results:

  • Case reports indicate associations between certain drugs and the development of DM and SSc.
  • The review assesses the strength of evidence for these drug-induced CTDs.
  • Specific substances are implicated in triggering these conditions.

Conclusions:

  • Drug exposure is a potential trigger for connective tissue diseases beyond lupus.
  • Further research is needed to confirm causality and identify specific offending agents.
  • Recognition of drug-induced CTDs is crucial for diagnosis and management.